A prospective cohort study of immunogenicity of COVID-19 vaccines in patients with autoimmune and inflammatory rheumatic diseases
Latest Information Update: 02 Jan 2023
At a glance
- Drugs Ad26.COV2 S (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 02 Jan 2023 New trial record
- 14 Nov 2022 Results presented at the ACR Convergence 2022